Pressmeddelande —
Axcentua Pharmaceuticals obtains US Patent rights for its clinical candidate, AXP107-11
The United States Patent and Trademark Office (USPTO) has issued Axcentua Pharmaceuticals the USPTO patent no 7, 863, 325 B2 entitled “Crystalline Genistein Sodium Salt Dihydrate”. The patent covers Axcentua’s novel crystalline composition of genistein, AXP107-11 and its medical uses. AXP107-11 is currently in phase Ib/IIa clinical trials for pancreatic cancer at the Karolinska University Hospital in Huddinge, Sweden.
“We are very pleased to have received the patent grant after an examination period of only 13 months” says Dr. Stefan Rehnmark, CEO of Axcentua Pharmaceuticals. “The Patent is proof that meaningful intellectual property can be obtained through crystal-re-engineering of natural compounds and it is rewarding to see the original business idea validated.”
About Axcentua Pharmaceuticals:
Axcentua Pharmaceuticals is a privately held early clinical development stage pharmaceutical company committed to the generation of investigational new drugs for diseases with high unmet medical need. The company was founded in 2007 by Dr. Anders Berkenstam, Dr. Stefan Rehnmark and Dr. Michael Robin Witt. Axcentua is pioneering a crystal re-engineering strategy of natural compounds, single small molecular entities, as a novel approach in drug development. Candidate drugs can be developed faster, with less risk and at a fraction of the cost as compared to traditional drug development.
Natural compounds have a proven track record as drugs and represent a largely untapped resource of new drug development candidates. However, natural compounds may have unfavorable drug-like properties and intellectual property issues have in many cases hindered the development of these compounds into successful drugs. By improving the drug-like properties and obtaining IP on novel forms, Axcentua’s crystal re-engineering strategy opens up new opportunities to explore and develop this rich source of small molecule compounds into drugs with clear pharmaceutical benefits.
For further information please contact:
Dr. Stefan Rehnmark, CEO
+46 8 524 88 620
+46 73 6478842
stefan.rehnmark@axcentua.com
www.axcentua.com
Ämnen
- Hälsa, sjukvård, läkemedel
Axcentua is a privately held early clinical development stage pharmaceutical company committed to the rapid generation of investigational new drugs for diseases with high unmet medical need, with an initial focus on cancer. The Company is pioneering the field of "crystal re-engineering" of natural compounds as an alternative drug development strategy to arrive at novel drugs with clear clinical benefits more rapidly, with less risk and at a fraction of the cost compared to traditional drug development strategies.
